Dubovsky Filip's Insider Trades & SAST Disclosures
Dubovsky Filip's most recent trade in Novavax, Inc. was a trade of 12,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Dubovsky Filip.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 12,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Sale of securities on an exchange or to another person at price $ 14.46 per share. | 17 Jun 2024 | 12,500 | 68,017 (0%) | 0% | 14.5 | 180,750 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.09 per share. | 17 Jun 2024 | 12,500 | 80,517 (0%) | 0% | 6.1 | 76,125 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.97 per share. | 17 Jun 2024 | 1,404 | 68,017 (0%) | 0% | 7.0 | 9,786 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2024 | 1,404 | 46,324 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Sale of securities on an exchange or to another person at price $ 14.54 per share. | 17 Jun 2024 | 1,404 | 66,613 (0%) | 0% | 14.5 | 20,414 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Sale of securities on an exchange or to another person at price $ 13.90 per share. | 14 May 2024 | 47,312 | 38,953 (0%) | 0% | 13.9 | 657,637 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 19,652 | 47,728 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.97 per share. | 14 May 2024 | 19,652 | 86,265 (0%) | 0% | 7.0 | 136,974 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,376 | 69,210 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,376 | 5,376 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.45 per share. | 10 Mar 2024 | 2,597 | 66,613 (0%) | 0% | 5.5 | 14,154 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 19,444 | 73,226 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 19,444 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.61 per share. | 07 Mar 2024 | 9,392 | 63,834 (0%) | 0% | 5.6 | 52,689 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 144,000 | 144,000 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | 14 Dec 2023 | 2,833 | 55,150 (0%) | 0% | 5.7 | 16,120 | Common Stock | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | 14 Dec 2023 | 2,833 | 0 | - | - | Restricted Stock Units | ||
| Novavax, Inc. | Dubovsky Filip | President, R&D | 14 Dec 2023 | 1,368 | 53,782 (0%) | 0% | 5.7 | 7,784 | Common Stock | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2023 | 1,400 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.06 per share. | 05 Nov 2023 | 1,400 | 52,994 (0%) | 0% | 7.1 | 9,884 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.06 per share. | 05 Nov 2023 | 677 | 52,317 (0%) | 0% | 7.1 | 4,780 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2023 | 12,644 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.71 per share. | 16 Sep 2023 | 12,644 | 57,702 (0%) | 0% | 7.7 | 97,485 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.71 per share. | 16 Sep 2023 | 6,108 | 51,594 (0%) | 0% | 7.7 | 47,093 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 4,155 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Jun 2023 | 4,155 | 47,065 (0%) | 0% | 8.0 | 33,406 | Common Stock |
| Novavax, Inc. | Filip Dubovsky | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.04 per share. | 16 Jun 2023 | 2,007 | 45,058 (0%) | 0% | 8.0 | 16,136 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges